Mind Medicine (MindMed) Inc., a biopharmaceutical company focused on developing treatments for brain health disorders, has announced new compensation terms involving inducement grants for three newly hired non-executive employees. The grants consist of options to purchase a total of 53,350 common shares of the company, with effective grant dates of May 5, 2025, and May 19, 2025, depending on each employee's start date. These options will vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in equal monthly increments over the subsequent three years, contingent on continued employment. The options were granted outside of MindMed's equity incentive plans and were approved by the company's Compensation Committee in accordance with NASDAQ regulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.